Modality expansion. Theranostics. Medical oncology integration. New sites of care. Every one of them is a capital decision made under reimbursement conditions that will not hold still.
We build the plan and pressure-test it before anyone commits.
Most Growth Plans Are Built Backward
The usual sequence: a vendor presents a technology, a physician champions it, a pro forma gets built on the vendor’s volume assumptions, and capital is committed. Operational capacity and payer behavior get examined after the equipment arrives.
That is how health systems end up with a program that is clinically excellent and financially underwater. Breaking the cycle of vendor-biased capital expenditure means running the analysis before the enthusiasm, not after it.
What We Do
Modality and Program Expansion
Theranostics, radiopharmaceuticals, and advanced therapies assessed for reimbursement durability and operational readiness, not just clinical merit.
Medical Oncology Integration
Connecting radiation, medical, infusion, pharmacy and 340B into one performance picture instead of five.
Market and Referral Analysis
Where volume actually originates and where it leaks out of the system.
Capital Strategy
Modeled against total cost of care and real-world operational capacity before commitment.
The Audit Comes First
Every engagement begins with an independent audit of operational performance and financial sustainability across the oncology service line. We are industry operators, which means no onboarding period and no learning curve.
What comes out is a defensible path with the assumptions exposed, tested against total cost of care and real-world capacity before anyone signs anything.
A growth opportunity assessment evaluates expansion options against operational capacity, reimbursement durability, and total cost of care.
